Selecta Announces More than $20 Million in Equity Funding

posted in: News | 0

Selecta Biosciences, Inc., a clinical stage biotechnology company developing a novel class of targeted antigen-specific immune therapies, today announced it has secured equity funding of more than $20 million from new and all of Selecta’s existing investors. “With strong financial … Continued

Emulate Launches to Commercialize Automated Human Organs-on-Chips Platform to Accelerate Drug Development, Detect Toxicities and Advance Personalized Medicine

posted in: News | 0

Emulate, Inc. today announced the company’s launch with a $12 million Series A financing to commercialize a first-in-kind, automated ‘Organs-on-Chips’ platform that mimics human physiology and diseases, while permitting real-time elucidation of molecular mechanisms of action and toxicity. Emulate’s proprietary … Continued

Selecta Accelerates Immune Tolerance Therapeutics and Announces New Product Candidate, SEL-212, for Refractory and Tophaceous Gout

posted in: News | 0

Selecta Biosciences, Inc.,a clinical stage biotechnology company developing a novel class of targeted antigen-specific immune therapies, today provided an update on the company’s product development pipeline, revealing its focus on immune tolerance applications of its proprietary Synthetic Vaccine Particle (SVP) … Continued

Charles Rowland Elected to BIND Therapeutics Board of Directors

posted in: News | 0

BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called AccurinsTM, announced that at BIND’s annual meeting of stockholders held today the company’s stockholders elected Mr. Charles A. Rowland, Jr., CPA, most recently the … Continued

BIND Therapeutics Presents Clinical Data Highlighting Unique Attributes of Lead Cancer Drug Candidate, BIND-014, at AACR 2014 Annual Meeting

posted in: News | 0

BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins™, announced today that clinical data on its lead drug candidate, BIND-014, were presented at the American Association of Cancer Research (AACR) meeting. The … Continued

Twist Bioscience secures $26M Series B and $5.1M from DARPA

posted in: News | 0

Twist Bioscience today announced that it raised $26 million in a Series B financing to commercialize the company’s semiconductor-based synthetic gene manufacturing process. Nick and Joby Pritzker, through their family’s firm Tao Invest, led the round, with participation from ARCH … Continued